CLDWW · Calidi Biotherapeutics, Inc. · Shareholders & Ownership
Substantial doubt about the company's ability to continue as a going concern.
“The Company estimates that based on the Company's liquidity resources, there is substantial doubt about the Company's ability to continue as a going concern within 12 months from the date of issuance of these unaudited condensed consolidated financial statements.”View the 10-Q filed Aug 13, 2026
Every disclosed holder of CLDWW in one list: 13F institutions, Schedule 13D and 13G filers, insiders (Forms 3, 4 and 5) and registered funds, each from its own latest filing. Holders nest by CIK and SEC reporting links, never by name, and each is summed once.
Who Owns CLDWW
13F quarter Dec 31, 2024; this listing alone: insiders and shares outstanding are issuer-wide, so they are left outNo chart: shares outstanding cannot be set against these holders.
| Holder group | Shares | % Out |
|---|---|---|
| Institutional (13F) | 105,000 | — |
| Insiders (Forms 3, 4, 5) | 0 | — |
| 13D/G-only blocks | 0 | — |
| Registered funds (N-PORT, not summed) | 0 | — |
% Out is unavailable: shares outstanding is an issuer-wide count, not one listing's.
13D/G-only counts each filer's latest 13D or 13G that no 13F report of the listing contains, that names no 13F filer and that no counted insider files. Funds are never summed: their shares sit inside their advisers' 13F reports.
Holders of CLDWW
| # | Holder | Shares | As of | Notes |
|---|---|---|---|---|
| 1 |
Exos Asset Management LLC
13F
CIK 1834630 · Registered investment adviser · Dec 31, 2024
|
105,000 |
Shares are restated onto today's split basis. Change compares each row with the same holder's previous filing in the same source; a dash means there is none to compare. Nested 13D/G, insider and fund rows are not summed, since a 13F report already holds them.